MDM2 and MDMX are well characterized as negative regulators of the tumor suppressor p53 and have been proven to contribute to cancer initiation, progression, and metastasis, as well as the resistance to chemotherapy (Hernandez-Monge et al., 2016; Karni-Schmidt et al., 2016). The gene discussed is MDM2; the disease is cancer.